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1. Introduction 
The stenotic degenerative aortic valve disease is a slowly developing condition. This 
condition is the result of an active process. Recently, it has been discovered that 
programmed cell death plays a major role in this progression (1-4). Stenotic degenerative 
aortic valve disease obstructs the outflow of the left ventricle (LV) and causes a pressure 
overload, with all its undesirable consequences. Once the disease has become symptomatic, 
the prognosis without surgical replacement of the valve is dismal: the life expectancy is 
reduced to 2 or 3 years with occurrence of syncope, angina pectoris and certainly with 
dyspnea (5). Age, left ventricular dysfunction and neurologic condition played a major role 
in the denial for AVR (6). Medical treatment and balloon valvotomy (7) do not improve the 
prognosis. Aortic valve replacement (AVR) is the only way to prolong life and improve its 
quality. In spite of technical improvements, the procedure involves a major procedure, with 
all its complications. Moreover, one condition (the valve disease) is replaced by another (the 
prosthetic valve).  
The possible hospital or 30 day complications which can occur after AVR include valve 
related, cardiac non-valve related and non-cardiac events. Identification of their predictors 
could lead to an improved referral pattern and, hence to an improved 30 day outcome, 
provided these predictors are liable to changes. 
2. Methods 
In one centre for cardiac surgery, 1000 patients who underwent AVR with Carpentier-
Edwards cardiac valve, were studied in a retrospective way. The operations were performed 
between the end of 1986 and the end of 2006. In most patients with degenerative aortic valve 
disease, coronary artery disease was also present. Hence, patients who received concomitant 
CABG were also included. Their median age was 75 (71-77) years. The surgical technique 
remained largely unchanged and was performed through a median sternotomy. After 
opening the pericardium, the ascending aorta, the vena cava inferior and superior could be 
accessed for connection to the extracorporeal circulation. The pulmonary artery was ligated 
temporarily in a gentle way. A vent was placed through the left superior pulmonary vein in 
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order to decompress the left ventricle. Before the extracorporeal circulation was started, the 
patient was fully heparinized. The patient was cooled to 30° Celsius and the heart was 
stopped and topically cooled with sludge ice. Systemic blood pressure, central venous 
pressure and left atrial pressure were continuously monitored. The ascending aorta was 
opened and cold cardioplegia was instilled within the coronary arteries. In case of severe 
coronary artery disease, additional cardioplegia was instilled through the coronary sinus. 
This was repeated after 30 minutes. The calcified aortic valve was inspected and excised. 
The ring was decalcified if necessary. The interrupted sutures were placed as three separate 
series through the aortic annulus, and then through the prosthesis in the same order. The 
valve was lowered into the annulus and the sutures were tied and severed at the desired 
length. If necessary, the great saphenous vein was harvested by another team for 
concomitant CABG. The suturing of the bypass on the coronary arteries were performed 
during the same clamping. The aortotomy was closed with a double running suture and the 
proximal end of the bypasses were also connected. The internal mammary artery was not 
often used. The extracorporeal circulation was stopped stepwise and then disconnected. 
Temporary pacemaker wires were attached to the surface of the ventricles. After thorough 
hemostasis and placement of drains, the chest cavity was closed. The patient was transferred 
to the intensive care unit and kept under sedation for 24 hours. In 1996, the anesthesia 
changed into a “short-track” procedure: the sedation was shortened from one day to 6 hours 
and extubation was performed as soon as possible thereafter. 
The changes is referral pattern were documented by comparison of age and co-morbid 
conditions in four periods of 5 year (1986-1991; 1992-1996; 1997-2001 and 2002-2006). A chi-
square analysis was used as statistical analysis to show significant differences over time.  
Twenty five preoperative and five peri-operative factors were screened in two steps. In a 
first step, the effect on hospital events was studied by an univariate chi-square or a Fisher-
exact analysis. In a second step, the significant factors were entered in a multivariate logistic 
regression analysis in order to identify the predictors.  
The results are presented for each risk factor (first column of the table), n/N (second 
column), p or probability (third column), OR (fourth column) and 95%CI (last column), 
where N is the number of patients at risk (i.e. having the risk factor) and n the number of 
these patients who suffered the complication; OR is the odds ratio and 95%CI is the 95% 
confidence interval.  
These factors were defined or dichotomized if appropriate and numbers are given.  
Octogenarians   186 
Male gender   530 
COPD (chronic obstructive pulmonary disease) 
    235 defined on protocol by pneumologist 
Impaired renal function  109 plasma creatinine over 1.3 mg% 
Previous carcinoma  104 proven by histologic examination and treated  
     with curative intent 
Hypertension   654 blood pressure repeatedly over 140/90 mmHg  
     in resting conditions 
Diabetes    149 treated by diet, peroral antidiabetics or insulin 
Coronary artery disease  631 documented on coronarography  
Myocardial infarction  151 documented by ECG, enzymes (during  
     previous admission) 
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Previous CABG   81 previous admission and operation protocol 
Carotid artery disease  238 stenosis of 40% or more on Doppler-duplex 
History of TIA/CVA (Transient ischemic attack / cerbrovascular accident) 
    40/68 by history and CT (computer tomography),  
     during previous admission 
Left ventricular dysfunction 247 decrease documented by segmental analysis of  
     ventricular wall on echocardiography 
LV ejection fraction<50%  155 calculated by data obtained at  
     echocardiography 
Atrial fibrillation   197 chronic or paroxysmal, documented by ECG 
Ventricular arrhythmias  74 documented by Holter monitoring 
Heart failure   216 at least one previous admission for pulmonary  
     edema 
NYHA (New York Heart Association) class IV 
    251 by anamnesis at admission for AVR 
Need for digitalis   152 by anamnesis at admission for AVR 
Conduction defect  270 documented by ECG: of any type and of any  
     degree 
First degree AV (atrioventricular) block 
    33 ibid  
Previous PaceMaker implant 33 during previous admission  
Previous endocarditis  17 documented by bacteriological analysis during  
     previous admission 
Need for urgent AVR  25 condition needing AVR at the same day in  
     order for the patient to survive 
Cross-clamping>75 min  460 sum of cross clamping time for valve  
     implantation and for additional procedures 
Valve size 19   27 sizes ranging from 19 to 27 
Concomitant CABG  610  
Mitral ring   13  
Aortoplasty   61 enlargement of reduction of the ascending aorta 
Carotid endarterectomy  22  
 
The adverse events under scrutiny were 
- hospital mortality (n=37) 
- valve related events 
 endocarditis, documented by clinical signs, echocardiography and blood samples 
(n=2) 
 thrombo-embolism, with neurological signs (n=25), documented on CT or ischemic 
events on other locations (n=2) 
 bleeding, evident if external or documented on cerebral CT (n=20) 
 ventricular arrhythmias, documented on ECG (n=37) 
- cardiac events not related to the valve 
 congestive heart failure defined by the inability of the heart to maintain an 
adequate circulation without support of inotropics or assist device (n=36) 
 conduction defects (new or progression of an pre-existing defect), documented on 
ECG, of any type and of any degree (n=101) 
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 atrial fibrillation, new or recurrence of a previously paroxysmal atrial fibrillation, 
documented on ECG (n=381) 
- non-cardiac events 
 acute renal function impairment, documented by an increase of plasma creatinine  
with 0.3 mg% (n=53) 
 pulmonary complications: clinical and radiological signs of atelectasis or 
respiratory infection or prolonged intubation (n=58).  
3. Results 
Between the end of 1986 and 1991, 80 patients received a Carpentier-Edwards valve in aortic 
position. This number was 216 between 1992 - 1996, 345 between 1997 - 2001 and 365 
between 2002 and the end of 2006. In our series, the changes in the four 5-year periods 
showed a significant increase in time for 
- patients over 80 (from 6,3% to 25,5%),  
- diabetes: 6.5% to 22.7%;  
- COPD: 6.5% to 36.4%;  
- renal function impairment: 0.9% to 17.7%;  
- carotid artery disease: 2.5% to 40.1%;  
- preoperative period of congestive heart failure: 12,5% to 28.3%;  
- previously performed CABG: 1.3% to 11.3%;  
All increases were highly significant (p<0.001). Only for the need of digitalis, a significant 
decrease was observed: from 39.7% to 9.4% (p<0.001). These results show that patients 
referred for AVR became older and have more co-morbidity. The reduction of use of 
digitalis could be due to the introduction of ACE inhibitors, angiotensin receptor, renin and 
beta blocking agents.  
The hospital results showed a completely different pattern. Only for non-cardiac 
complications, a significant increase (p=0.001) has been found over time, from about 20% in 
the first two five-year periods to about 30% in the last two five-year periods. Mortality and 
major cardiovascular complications rates such as ventricular arrhythmias, bleeding, 
congestive heart failure and thromboembolism all remained well below 5% throughout 
these observation periods, without a noteworthy increase. Atrial fibrillation remained 
between 30 and 40%, without an increase over time.  
Although patients referred for AVR became older and sicker, 30-day postoperative survival 
seemed not affected. Therefore, age and the presence of co-morbid conditions do not 
necessarily represent formal contra-indications for AVR. Nevertheless, an increase of non-
cardiac postoperative complications with concomitant increase in length of stay and use of 
economic resources could be expected if older and sicker patients are operated upon.  
Hospital or 30 day mortality  
Significant preoperative factors for mortality in an unvariate analysis were: 
P<0.001: need for urgent surgery, age over 80, decreased left ventricular function,  
P<0.01: renal function impairment, LVEF below 50%, previous AMI, previous 
heart failure, need for digitalis, 
P<0.05: diabetes, chronic or paroxysmal atrial fibrillation, 
The other risk factors had no significant effect. NYHA functional class II had a protective 
effect (p<0.001) for mortality.  
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Multivariate analysis showed following results 
Factor  n/N  p  OR  95%CI  
Urgent AVR  7/25  <0.001  9.0  2.8-28.7 
Digitalis  12/152  0.002  3.5  1.6-7.7 
Age > 80  17/186  0.005  3.1  1.4-6.6 
 
Mortality in the hospital phase was the most important outcome. It varied between 1.5% (8) 
and 24% (9). These differences were due to large differences in patient characteristics such as 
age and co-morbid conditions. With a time span of almost 20 year between the first and the 
last publication, improvement in surgical techniques and peri-operative care could also be 
responsible for these differences in mortality. 
In most series, the hospital mortality was below 10%. In series where the mortality was over 
10%, several risk factors were usually present. Independent predictors for hospital mortality 
were identified and confirmed that specific co-morbid conditions increased the early 
postoperative risk.  
Most of these factors could be related to the left ventricle and hence to the patient. An 
emergency need for AVR (i.e. to operate on the same day as the admission in order for the 
patient to survive) has been identified as the most important predictor, with a increase of 
mortality of 10 times (10). This has been confirmed in other series (11,12). This indicated to 
an exhaustion of all compensatory mechanisms to maintain an adequate circulation. A need 
for urgent AVR has also been identified as a predictor for early postoperative congestive 
heart failure, which is a highly lethal condition (13). A high preoperative functional class 
NYHA IV (14,15) and a low-flow low-gradient problem also could be related to a protracted 
burden, and hence a decreased left ventricular function. Coronary artery disease, previous 
and the need for concomitant CABG (9,11,12,15) as well as a previous myocardial infarction 
(10,11) and previous CABG (12) could add to a decrease in left ventricular function.  
Valvular factors such as severity of valvular disease and the type and size of valve 
prosthesis implanted also had an effect (15,16). The effect of non-cardiac factors such as 
diabetes (15) and renal disease (11,12,17) was also observed. Remarkably, the effect of age 
over 80 (9,12,18,19), although important, was less compared to the effect of need for urgent 
surgery on mortality(10).  
Thromboembolic events 
TE events were one of the most important and devastating events after AVR, especially if 
permanent neurological deficit was present. One also has to keep in mind that many TE 
events go unnoticed. In one small series, MRI after cardiac surgery could document silent 
events in 6 of 34 patients, which is rather high (20). We found this clinically evident 
thromboembolism in 27 of 1000 patients. In 25 cases, this was neurological. An univariate 
analysis identified a decreased left ventricular function (p<0.01) as sole risk factor.  
This risk factor was confirmed in a multivariate analysis, which showed an ejection fraction 
below 50% as an independent predictor (11/247 patients), with p=0.027, an odds ratio of 2.5 
with a 95% confidence interval between 1.1-5.7.  
Some studies  reported on the predictors for thromboembolism after AVR on long-term and 
none reported on such events on short-term. The short-term thromboembolic events, 
however, have their importance since these are a predictor for future events (21). A 
preoperative CVA seemed to have a comparable significance (21-24) for long-term events.  
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A low ejection fraction also has been identified as predictor (24). Congestive heart failure 
and a dilated ventricle are known risk factors for thromboembolism. Damage to the 
ventricular wall as well as an abnormal flow of blood (and possible stasis) can promote 
intra-ventricular thrombosis and hence embolization. If the LVEF is below 30%, life-long 
anticoagulation is required (25).  
Age also has been identified as an independent predictor (23-27). The age distribution of any 
given patient population should be made known to appreciate fully the effect of this factor. 
Age might be related, however to co-morbid conditions such as diabetes and atheromatosis 
of the aorta and the cerebral vessels (23,24).  
Carotid artery disease could be a matter for debate. In some series (23,24), it was identified 
as a predictor for thromboembolism, in other series, this was not (21). A Doppler-duplex  
investigation is a reliable tool for the detection of lesions and is routinely performed in some 
institutions. It cannot, however, detect atheromatosis of the intracranial vessels.  
A long ECC time (24) might indicate to coronary artery disease (28) and hence, to the need 
for an associated procedure, which mostly is a CABG. This could confirm atheromatous 
vessels as a possible source for thromboembolic events. These cannot be considered entirely 
as valve related. A “smoking gun”, however, is often not found. And CABG itself has never 
been identified as a predictor for thromboembolism.  
AF could also be a matter for debate: it is certainly a risk factor for thromboembolic events. 
However, it is also an indication for anticoagulation, which might cloud the effect of AF. In 
some series, AF was identified as a predictor (28), in others not (21,24).  
It is by no means certain that risk factors for long-term thromboembolic events could be 
used to predict the occurrence of such events on short term. The latter, however, have their 
prognostic significance. Moreover, all these predictors indicate that the sources of 
thromboembolic events are multiple. Hence thromboembolism cannot be considered as 
entirely valve related (21,29), but also as patient related.  
To prevent thromboembolism after AVR with a biological prosthesis, anticoagulant 
medication is given for three months after implantation, after which it can be replaced by 
acetyl salicylic acid, with good results (21), unless anticoagulants are indicated for another 
reason. An RCT to support this strategy does not exist (25), but the general idea is that 
vitamin K antagonists protect against early thromboembolism while re-endothelialization of 
the stent and the sutures is not yet complete. For mechanical heart valves, a life-long 
anticoagulant treatment is necessary. The target level for INR is determined by the valve 
position (for aortic this is lower than for mitral) and by the type of mechanical heart valves. 
Older types such as cage ball devices are more thrombogenic and require deeper 
anticoagulation. A strict classification for thrombogenicity is not available. There are too 
many patient related factors involved (25).  
Bleeding events 
Univariate analysis revealed three factors with a significant effect. This was confirmed by a 
multivariate analysis. The use of vitamin K antagonists could not be included since almost 
all patients received this medication for three months after operation. The three predictors 
were: 
Factor   n/N  p  OR 95%CI  
Concomitant CABG  17/610  0.046  3.6 1.0-12.5 
COPD   8/235  0.051  2.6 1.0-6.6 
Aortoplasty   4/61  0.058  3.5 1.0-12.6 
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Bleeding events could be considered as the other side of the coin of anticoagulation with 
vitamin K antagonists. Effective protection against thromboembolism holds the risk for 
bleeding. A continuous balance should be made. The INR does not only depend on the dose 
of vitamin K antagonists, but also on the adsorption of vitamin K by the mucosa of the colon 
and on its processing by the liver. No other reports concerning predictors for early bleeding 
after valve replacement appeared. Current results indicated that early bleeding seems 
related to the procedure and is different compared to bleeding events at long term, which is 
probably more related to anticoagulation. Nevertheless, other factors such as age and 
increased cardiothoracic index were identified as predictors for bleeding during long-term 
follow-up (26). Fragility in elderly might be an important reason. In other series, no 
predictors or risk factors could be identified (30,31).  
Prosthetic valve endocarditis 
The number of patients with early prosthetic valve endocarditis was low, hence no risk 
factors or predictors (such as preoperative endocarditis) could be identified in our series. 
Literature data only described long-term events.  
The linearized rate for long-term prosthetic valve endocarditis was low and mostly under 
1% per patient year (26,27,32-39). The most event free rates after 5 to 25 year were well over 
90%. This was true for mechanical heart valves (35,40,41) as well as for the different stented 
(30,42) and stentless tissue valves (27,36,43) as for homografts (8). No risk factors could be 
identified, although a previous endocarditis could arouse some suspicion. Prosthetic valve 
endocarditis carried a high risk for mortality, especially if Staphylococcus aureus has been 
detected (44). These micro-organisms often lead to ring abscesses and prosthetic 
paravalvular leak. The occurrence of congestive heart failure with prosthetic valve 
endocarditis has been the main indication for re-operation (45).  
Congestive heart failure 
Univariate analysis identified following risk factors: 
P<0.001: Need for urgent surgery, chronic or paroxysmal atrial fibrillation  
P<0.01: Age over 80, decreased left ventricular function, previous infarction  
P<0.05: COPD, LVEF below 50%, preoperative heart failure, need for digitalis  
NYHA class II had a protective effect (p<0.001) 
Multivariate analysis showed following results 
Factor  n/N  p  OR  95%CI  
Urgent AVR  7/25  <0.001  10.5  3.6-30.8 
Atrial fibr.  16/197  0.001  3.5  1.7-7.4 
EF<50%  10/155  0.055  2.1  1.0-4.4 
 
In-hospital congestive heart failure after AVR is a highly lethal complication (13,46). 
Hospital heart failure occurred in 2.6% of the patients in an earlier series (13), with need for 
urgent AVR as the sole independent predictor. This pointed to an exhaustion of all 
compensatory mechanisms to maintain an adequate circulation and this observation should 
reason not to postpone AVR, once it has become symptomatic. In another study, the level of 
B-type natri-uretic peptide was also identified as a predictor (46). Apoptosis or programmed 
cell death of cardiomyocytes could be an important event in these patients (47). Atrial 
fibrillation could lead to a decreased ventricular filling and cardiac output since the atrial 
contraction is lost. In an earlier series, this was also the case in long-term heart failure (13). 
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Early congestive heart failure should be distinguished from long-term heart failure: the 
latter was diastolic in nature and has some other risk factors such as conduction defects and 
coronary artery disease. An impaired relaxation occurred since after regression of the 
muscle mass, this fibrosis persists for a longer time. This stiffened the LV wall (48). The 
LVEF remained often normal. Hence, this could be labeled as a “diastolic” form of CHF (13).  
Concurrent conduction defects thereby could lead to perfusion defects and wall motion 
abnormalities, even in absence of coronary artery disease (49). Biventricular pacing often 
could correct this condition (50,51). Coronary artery disease could lead to ischemic loss of 
myocardial contractility, adding to the left ventricular function. Concomitant CABG, 
however was not identified as a predictor for postoperative CHF (13).  
A small valve size has not been identified as a predictor for long-term heart failure in a 
previous series (13), neither in the current series for short-term heart failure. Hence, in 
patients with a small aortic root, it seemed not necessary to enlarge the root or to implant a 
stentless valve, which requires a more demanding technique, provided the LVF is normal.  
However, it becomes important in patients with a low ejection fraction. When, in such 
patients, a small valve size leads to an even moderate prosthesis-patient mismatch, this 
might result in heart failure and an increased mortality (52).  
Atrial fibrillation 
Atrial fibrillation and other non-sinusal rhythms occurs in 20% of the postoperative patients 
(32). In other series, this was 40% or more (53,54). The definition and the diagnostic method 
for AF have also an effect on its incidence (54,55). Postoperative AF has not been considered 
as innocent: it could lead to other complications and an increased stay in the hospital. With 
atrial fibrillation, there was a higher incidence of postoperative mortality (54) heart failure, 
renal function impairment, infection and neurologic events (53).  
Univariate analysis showed following risk factors 
P<0.01: Previous PTCA  
P<0.05: LVEF below 50%  
In a multivariate analysis, previous PTCA was the only independent predictor (p=0.006; 
odds ratio 2.7; 95% confidence interval 1.3-5.4) 
The risk factors for postoperative AF in other series were a history of paroxysmal atrial 
fibrillation, a large left atrium, a prolonged P wave, heart failure, high age, low ejection 
fraction and left ventricular hypertrophy (55-57). The effect of age, however remained a 
matter for debate: atrial fibrillation did not occur more frequently in octogenarians after 
AVR (27).  
It seems that postoperative atrial fibrillation was preventable, at least in part. Pacing could 
half the frequency of this event (53). Timely and adequate treatment could increase the 
speed of postoperative rehabilitation and reduce the stay within the hospital (55).  
Conduction defects 
An univariate analysis showed as risk factors:  
P<0.001: preoperative heart failure 
P<0.01:  carotid artery disease, concomitant CABG  
P<0.05: NYHA functional class IV  
An AV block grade 1 showed a trend. A large valve size (27 mm) had no effect.  
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A multivariate analysis showed following results:  
Factor   n/N  p  OR 95%CI  
Preoperative heart failure  32/215  0.001  3.0  1.7-5.4 
Concomitant CABG  69/610  0.007  2.0 1.2-4.2 
NYHA class IV  23/249  0.039  1.9 1.0-3.4 
AV Block grade 1  7/37  0.078  2.4 1.0-5.7 
 
Conduction defects such as complete atrio-ventricular block, and hence permanent 
pacemaker implantation, occurred in almost 10%  of the patients who underwent AVR (58). 
The occurrence of all new conduction defects is reported to be 15% (59). Other reports state a 
lower incidence for permanent pacemaker implantation, since not all conduction defects 
need this treatment. Sometimes, a new conduction defects could be reversible (58). 
Development of a new conduction defects resulted to an increased need for monitoring and 
hence a longer hospital stay (60) 
The main predictor for permanent pace maker implantation in other series were 
preoperative conduction defects (58,61-63). Other predictors were female gender, annular 
calcification, bicuspid aortic valve, hypertension, myocardial infarction, electrolyte 
imbalance and prolonged cross-clamping time (60,64,65). Aortic regurgitation might also 
play a role since this condition usually required implantation of larger valves (58).  
Preoperative changes in the conduction system might be degenerative and due to older age, 
to ischemia and mechanical factors, due to an increased left ventricular pressure (58).  
Some factors such as a calcified annulus could lead to trauma of the conduction system 
during surgery. The link with a congenitally bicuspid aortic valve is less clear. Hypertension 
could lead to calcification but also to increased septal left ventricular hypertrophy, which 
makes the conduction system more difficult to protect during cross-clamping (60). Other 
traumas of the conduction system could be due to impingement by the prosthetic valve or 
by suturing (58).  
Development of a new conduction defects such as left bundle branch block in the 
postoperative period was a marker for future adverse events, such as sudden death (59), 
which illustrates the importance of these defects.  
Non cardiac hospital complications 
Pulmonary complications occurred in 58/1000 patients after AVR (66).  
Univariate analysis showed following risk factors 
P=0.001: postoperative heart failure 
P<0.01: preoperative PM implantation 
P<0.05: COPD 
Multivariate analysis identified following predictors:   
Factor   n/N  p  OR 95%CI  
Pacemaker implant  7/33  0.002  4.4 1.8 – 11.2 
COPD   21/235  0.073  1.7 0.95 – 3.1 
Heart failure   7/34  0.001  4.7 1.8 – 11.9 
 
Respiratory complications after AVR are common (9,66,67) but few reports appeared 
concerning their predictors. Their rate depends largely on the criteria used (need for 
prolonged ventilation, respiratory failure, pulmonary infection).  
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The basic mechanisms of these complications involved a lack of deep inspiration due to 
postoperative pain, with a shallow breathing pattern, a prolonged recumbent positioning, a 
temporary diaphragmatic dysfunction and an impaired mucociliary clearance with a 
decrease in cough effectiveness, increases the risks associated with retained pulmonary 
secretions and bronchial obstruction (68). Atelectasis, infection and prolonged stay within 
the intensive care unit could be the result of such obstruction (69,70).  
The use of an extracorporeal circulation during cardiac operations certainly has side effects 
on the respiratory system, due to inflammation (71,72). With greater hemodilution this effect 
could increase resulting pulmonary edema and pneumonia, especially when endothelial 
cells are injured (73). Pulmonary edema was also a hallmark of postoperative heart failure, 
which has been identified as a clear risk factor for postoperative pulmonary complications. 
Chronic obstructive pulmonary disease could worsen the production of mucus, thereby 
increasing the risk for atelectasis and infection. Early postoperative heart failure, and hence 
pulmonary edema increase the need for ventilator support and prolong the stay on ICU. This 
also could make the patient more vulnerable for postoperative pulmonary problems (66). 
In 58 of 1000 patients, we observed renal function impairment after AVR (17). Renal and 
cardiovascular disease could be linked in two ways. On the one hand, renal function 
impairment, even if this modest, has been an established element in the risk profile for 
atheromatosis (74,75). On the other hand, renal function impairment could also be the result 
of atheromatosis and has certainly been observed after major cardiovascular surgery such as 
AVR. Postoperative decrease of the renal function has been considered a serious 
complication with an increased mortality rate.  
The risk factors in an univariate analysis for this complication were 
Preop. renal impairment  22/108  29/890  <0.001 
Age > 80    22/186  31/814  <0.001 
Preop. atrial fibrillation  22/197  29/803  <0.001 
Preop. pulmonary oedema  22/216  31/781  0.001 
Preop. conduction defect  24/270  28/721  0.002 
Diabetes    15/149  37/851  0.006 
Preop. myocardial infarction  15/151  36/849  0.006 
Postop. heart failure   6/34  47/966  0.007 
CCT >75 min. (complete procedure) 29/460  7/275  0.015 
Previously performed CABG  9/81  42/916  0.018 
concomitant CABG   39/610  14/390  0.031 
LV ejection fraction<0.50  13/155  31/723  0.033 
Previous TIA/CVA   10/108  41/892  0.035 
A multivariate analysis revealed following predictors  
Factor   p  OR  95%CI 
Preop. renal impairment <0.001  5.5  2.9 – 10.4 
Preop. atrial fibrillation 0.010  2.3  1.2 – 4.2 
Age > 80   0.014  2.2  1.2 – 4.1 
Myocardial infarction  0.022  2.2  1.1 – 4.4 
 
Age over 80 has been associated with an increase in atheromatosis and myocardial 
infarction is certainly a marker for it. If atheromatosis also affects the renal arteries, a 
postoperative decrease in renal function could be expected (17).  
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Endothelial dysfunction of patients with CAVS could be a link with renal function 
impairment. This could help explaining the observed association between preoperative AF 
and postoperative renal complications. There are, however, several confounding factors 
(76,77).  
Other risk factors were hypertension, peripheral arterial disease, bypass time over 70 
minutes, severe angina an non-elective surgery (67,78).  
Three difficulties could arise by comparing different series. First, the definition of previous 
renal function impairment as well as of postoperative decrease in renal function varied 
between series. In one series, a level of 2.0 mg/dl was used (78), in another 1.4 mg/dl (17). 
This could account for differences in results. The second difficulty has been the estimation of 
renal function: plasma creatinine , as a routine clinical procedure is not sufficient as estimate 
for glomerular filtration rate. Hence, its results should be interpreted cautiously. The 
estimation of glomerular filtration rate requires a 24-h urine collection, which is liable to 
errors. Third, defining a worsening of renal function by an increase of plasma creatinine  
(79) also had its difficulties: in patients with a plasma creatinine  between 1 and 2 mg and 
hence, a moderate degree in renal function impairment, an additional increase with 0.3% 
could mean a serious additional renal damage. In patients with higher initial plasma 
creatinine , such an increase does not mean necessarily a major change in renal function: the 
slope of the relation between glomerular filtration rate and plasma creatinine  is much less 
compared to the area with low initial plasma creatinine. 
The extracorporeal circulation could have a damaging effect on the glomeruli, especially if 
the kidney already has been injured. Mechanisms inflicting renal damage are non-pulsatile 
perfusion, renal hypoperfusion, hypothermia, and increased levels of circulating 
catecholamines, cytokines, enzymes, free radicals and free hemoglobin (80). Keeping the 
cross-clamp time as short as possible or installing a minimal ECC could be helpful (81,82).  
In spite of increasing age and co-morbid conditions in patients referred for AVR, the 
increase in  hospital complications seemed to be limited to non-cardiac complications, which 
have a lower fatality rate than cardiovascular complications (83). The occurrence of renal 
and pulmonary postoperative events should be taken into account, however, if one chooses 
to operate older and sicker patients with symptomatic aortic valve disease. 
4. Discussion and conclusions 
Postoperative mortality and valve related complications received much attention in most 
patients series. Recently, other cardiac complications such as heart failure, conduction 
defects and atrial fibrillation were also scrutinized. Univariate analysis as screening and 
subsequent multivariate analysis as identification of risk factors for each event could be 
helpful patient selection and, more importantly, improve postoperative results if these risk 
factors are liable for alteration.  
Mortality and congestive heart failure, which was identified as the most lethal cardiac 
complication, were clearly patient related. One might expect a reduction in these events if 
patients are referred early, once aortic valve degeneration has become symptomatic. This 
could avoid the appearance of a major risk factor, i.e. the need for urgent valve replacement. 
This is the clear consequence of a protracted pressure overload on the left ventricle by the 
diseased aortic valve and the ultimate marker for advanced heart valve disease. 
Thromboembolism and bleeding are typically considered as valve related events. The 
former, however, could also be related to patient factors, while the latter could also be 
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related to the procedure. Both events could have a significance as risk factor for long-term 
recurrence.  
Occurrence of early postoperative conduction defects and of atrial fibrillation could also be 
considered as markers of advanced valvular heart disease, since some of their risk factors 
might be the result of protracted pressure overload on the left ventricle. Hence, these events 
could be seen as patient related.  
Non-cardiac complications could clearly be related to co-morbid conditions. These, however 
are not always liable to alterations. Hence, the peri- and postoperative care should be 
tailored for each patient. It has also become obvious that age over 80 is not a formal 
contraindication for AVR. Nevertheless, elderly usually have considerable co-morbidity. 
The EUROscore, which was developed for CABG patients overestimates the risk for hospital 
mortality considerably. Low ejection fraction, chronic pulmonary obstructive disease and 
peripheral artery disease have been identified as predictors, although (84). Pulmonary 
function after median sternotomy is reduced in a substantial way, probably by several 
mechanisms such as chest wall restriction, decreased movement of the diaphragm and 
impairment of diffusion across the alveolar membrane (85). 
It seemed worthwhile, therefore, to explore some alternative techniques in valve surgery 
which could reduce the postoperative risk. These could be 1) minimal surgical access, 2) 
minimal extracorporeal circulation and 3) transcatheter aortic valve implantation. 
The first alternative, minimal surgical access by  ministernotomy (85-88) and anterolateral 
minithoracotomy (89-91) could expose the surgical field adequately. Possible indications 
could be obesity, chronic obstructive pulmonary disease (86) and previous chest irratiation 
or CABG with patent left internal mammary artery (91). 
Some advantages have been described such as an economic benefit, improved cosmetic 
result, decrease in postoperative morbidity, length of stay, pain, blood loss and transfusion 
(86-90,92). Cross clamping time had increased, however (88). Two randomized trials have 
appeared, which compared minimal and conventional AVR. The first one, was very small 
and included 20 patients for every group (88). The second one excluded patients with 
obesity and pulmonary disease (85), in spite of previously mentioned indications (86). Pain 
and blood loss were less, but there was no less need for transfusion. No other benefits  such 
as a decrease in renal or pulmonary complications or differences in postoperative 
pulmonary functions could be documented (85,88,93). Results in high risk patients were 
considered as excellent in a recent review, but randomized controlled trials comparing 
minimal with conventional AVR are needed (94). 
The second approach involves the changes in extracorporeal circulation devices. The use of 
an extracorporeal circulation during AVR has the risks of hemodilution and of an 
inflammatory response, which could be reduced by an minimal extracorporeal circulation or 
MECC. This MECC is a closed system with a centrifugal pump, an oxygenator without a 
venous and cardiotomy reservoir. The patient functions as the venous reservoir (95). This 
reduces the contact of blood with artificial surfaces and with air. The risk for hemolysis and 
the need for blood transfusions also decreases (96). With MECC, there is less increase in C-
reactive protein, troponin I level, and better preservation of platelets and renal function. 
Stroke and cerebral injury were also less. The improved biocompatibility of MECC is of 
special advantage in high risk patients (age over 65, renal and pulmonary dysfunction). The 
use of a minimal ECC involves a learning curve, however (82).  
More recently, TAVI or transcatheter aortic valve implantation, either through an artery or 
through the cardiac apex has been developed as third alternative. In patients deemed unfit 
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for conventional AVR, TAVI was compared to balloon valvotomy through a randomized 
controlled (PARTNER) trial. Mortality (30-day and one-year) from any cause and repeat 
hospitalization as well as occurrence of cardiac symptoms (higher NYHA functional class) 
were significantly reduced after TAVI. Major strokes, bleeding events and major vascular 
events occurred more often, however. Balloon valvotomy did not alter the course of aortic 
valve disease. Paravalvular leaks after TAVI were usually mild and did not worsen after one 
year. Postprocedural stroke was troublesome, but might be reduced by developing smaller 
delivering devices. These results cannot be extrapolated to patients in whom conventional 
AVR is an option (7). The trans-apical approach for TAVI is a feasible alternative in high risk 
elderly patients with symptomatic aortic valve disease and peripheral artery disease. There 
is no need for sternotomy or extracorporeal circulation. No post-procedural stroke was 
observed, probably due to the avoidance of an atheromatous aortic arch. Presence of 
preoperative respiratory dysfunction proved to be a risk. The procedural success rate was 
high. Compared to a control group of patients who underwent conventional AVR (by 
propensity score analysis), 30-day and one-year survival superior for trans-apical TAVI, but 
this difference was not significant (97).  
To document the superiority of either of these minimal approaches, RCT on sufficiently 
large scale are needed. For ministernotomy and minithoracotomy, these are feasible, but still 
lacking. For TAVI, it is currently unethical for patients to subject patients to the still 
unknown long-term results of TAVI if these are deemed fit for conventional AVR. 
Conventional AVR still can be considered as the standard therapy for degenerative aortic 
valve disease, with very predictable results, even in the elderly and patients with co-morbid 
condition.  
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